CINCINNATI, OH--(Marketwire - March 10, 2009) -
| Highlighted Links |
clinical research |
Medpace |
Having spent a majority of his career with Pfizer in the US, spearheading clinical development projects both domestically and internationally, Dr. Sauniere has most recently been involved entrepreneurially with early stage development compounds. His broad knowledge of the biotechnology and pharmaceutical industries also includes product licensing, distribution and relationship building at all levels. As a medical practitioner with experience in oncology and metabolism, Dr. Sauniere is a board certified Physician in France, and is a member of the both the US Licensing Executive Society and the American Society of Clinical Oncology.
"The addition of Dr. Sauniere to our group of European based scientists and regulatory experts gives Medpace the ability to deliver hands-on results for our multinational sponsors," said Dr. August Troendle, Medpace President and CEO. "I believe Dr. Sauniere's reputation as a clinical development professional with both early and late stage projects, as well as his deep business development relationships within the industry, will enable Medpace to continue our growth in Europe."
Dr. Sauniere, with medical expertise in oncology, gastroenterology and metabolism, will be located in Medpace's office in Zurich and will act as a Medical Director and Business Development Executive for projects in Europe.
ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, oncology, and nephrology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.
Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 700 global Medpace employees, 140 located in Europe, and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, oncology, and nephrology.
Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.
Visit the Medpace website at www.medpace.com
